Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Galectin Therapeutic (GALT)

Galectin Therapeutic (GALT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 172,798
  • Shares Outstanding, K 57,029
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,290 K
  • 60-Month Beta 2.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.10
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.43 +19.75%
on 05/11/20
3.20 -9.06%
on 05/26/20
+0.21 (+7.78%)
since 05/01/20
3-Month
1.50 +94.00%
on 03/19/20
3.55 -18.03%
on 04/30/20
+0.79 (+37.26%)
since 02/28/20
52-Week
1.50 +94.00%
on 03/19/20
4.50 -35.33%
on 11/11/19
-1.12 (-27.79%)
since 05/31/19

Most Recent Stories

More News
Galectin Therapeutics' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Galectin Therapeutics.

GALT : 2.92 (-1.02%)
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update

NASH-RX Clinical Trial Protocol Filed with FDA; First Patient Currently Expected to be Enrolled in Second Quarter 2020

GALT : 2.92 (-1.02%)
Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) its...

GALT : 2.92 (-1.02%)
Galectin Therapeutics Update on the Impact of COVID-19

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the impact of the COVID-19 pandemic on the Company and its clinical...

GALT : 2.92 (-1.02%)
Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December...

GALT : 2.92 (-1.02%)
Galileo Global Equity Advisors Inc. Completes Repurchase of all Shares owned by U.S. Global Investors (Canada) Ltd.

Galileo Global Equity Advisors Inc. ("Galileo") today announced that it has completed the previously announced purchase for cancellation of all of the 650,000 Class A common shares in the capital of Galileo...

GALT : 2.92 (-1.02%)
Galectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical Officer

Galectin Therapeutics Inc. (NASDAQ:GALT), a leader in the field of NASH therapeutics, today announced the appointment of Pol F. Boudes, M.D. to the position of Chief Medical Officer. In this position,...

GALT : 2.92 (-1.02%)
Galectin Therapeutics' President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020

Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin, the Company's President and CEO, will present at...

GALT : 2.92 (-1.02%)
Galileo Global Equity Advisors Inc. Announces Repurchase of all Shares owned by U.S. Global Investors (Canada) Ltd.

Galileo Global Equity Advisors Inc. ("Galileo") today announced that it has agreed to purchase for cancellation all of the 650,000 Class A common shares in the capital of Galileo owned by U.S. Global Investors...

GALT : 2.92 (-1.02%)
Galectin Therapeutics' Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology

Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper highlighting the results of its NASH-CX Phase 2 clinical trial...

GALT : 2.92 (-1.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade GALT with:

Business Summary

Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring...

See More

Key Turning Points

2nd Resistance Point 3.17
1st Resistance Point 3.10
Last Price 2.92
1st Support Level 2.91
2nd Support Level 2.79

See More

52-Week High 4.50
Fibonacci 61.8% 3.35
Fibonacci 50% 3.00
Last Price 2.92
Fibonacci 38.2% 2.65
52-Week Low 1.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar